The assessment of the level of growth factors in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy;Ocena poziomu czynników wzrostowych u młodzieży z cukrzyca̧ typu 1 i rozpoczynaja̧ca̧ siȩ angiopatia̧ cukrzycowa̧

Endokrynologia, Diabetologia i Choroby Przemiany Materii Wieku Rozwojowego

Volumn 10, Issue 1, 2004, Pages 41-48

  Peczyńska, Jadwiga ^a   Urban, Mirosława ^a   Urban, Beata ^b   Głowińska, Barbara ^a   Florys, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NONE   (Poland)

Author keywords

Diabetes mellitus type 1; Growth hormone; IGFBP 3; Insulin like growth factor 1; VEGF

Indexed keywords

GROWTH FACTOR; GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; VASCULOTROPIN;

ADOLESCENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC MICROANGIOPATHY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; EVALUATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3543113807     PISSN: 1234625X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Aiello L.P., Avery R.L., Arrigg P.G. i wsp.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 1994, 331, 1480.
2. Akinci A., Copelland K.C., Garmong A., Clemmons D.R.: Insulin-like growth factor proteins (IGFBPs) in patients with insulin-dependent diabetes mellitus. Metabolism, 2000, 49, 626.
3. Barkai L., Tomacz A., Soos A., Vamasi I.: Association of hormonal changes of puberty with microalbuminuria in adolescents with type 1 diabetes. Diabetologia, 2000, 43, supl. 1, A 256, 979 (EASD Jerusalem, 17-21 September).
4. Batch J.A., Werther G.A.: Changes in growth hormone concentrations during puberty in adolescents with insulin dependent diabetes mellitus. Clin. Endocrinol., 1998, 36, 411.
5. Bek E.L., McMillen M.A., Scott P. i wsp.: The effect of diabetes on endothelin, interleukin-8 and vascular endothelial growth factor-mediated angiogenesis in rats. Clin. Sci. (Colch.) 2002, 48, supl., 424S.
6. Brismar K.: IGF-I and IGFBP-I in Indian diabetic populations type 1, type 2 and malnutritional diabetes. Diabetologia, 2000, 43, supl. 1, 680 (EASD Jerusalem, 17-21 September).
7. Cameron N.E., Eaton S. E. M., Cotter M.A. i wsp.: Vascular factors and metabolic interactions in the pathogenesis of diabetic nauropathy. Diabetologia, 2001, 44, 1973.
8. Carroll P.V., Christ E.R., Bengtsson B.A.: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J. Clin. Endocrinol. Metab., 1998, 83, 382.
9. Chiarelli F., Spagnoli A., Basciani F. i wsp.: Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet. Med., 2000, 17, 650.
10. Clemmons D.R., Moses Ac., McKay M.J. i wsp.: The combination of insulin-like growth factor I and insulin-like growth factor - binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes; evidence for in vivo biological activity. J. Clin. Endocrinol. Metab., 2000, 85, 1518.
11. Crowne E.C., Samra J.S., Cheetham T. i wsp.: The role of IGF-binding proteins in mediating IGF-1 on insulin requirements in type 1 diabetes mellitus. J. Clin. Endocrinol. Metab., 2001, 8, 3686.
12. Cummings E.A., Sochett E.B., Dekker M.G. i wsp.: Contribution of growth hormone and IGF-I to early diabetic nephropathy in Type 1. Diabetes, 1998, 47, 1341.
13. Czech A.: Standardy w opiece diabetologicznej. Warszawa, PZWL, 1997.
14. Feldmann B., Jehle P.M., Mohan S. i wsp.: Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins. Growth Horm. IGF Res., 2000, 10, 53.
15. Garay-Sevilla M.E., Nava L.E., Malacara J.M. i wsp.: Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus. Diabetes Metab. Res. Rev., 2000, 16, 106.
16. Heald A.H., Cruiccckshank J.K., Riste L.K. i wsp.: Close relation of fasting cardiovascular risk in two populations. Diabetologia, 2001, 44, 333.
17. Hogeboom van Buggenum I.M., Polak B.C., Reicchert-Thoen J.W. i wsp.: Angiotensin converting enzyme inhibiting therapy is associated with lower vitreus vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia, 2002, 45, 203.
18. Hunt B.J., Jurd K.M.: Endothelial cell activation - a central pathophysiological process. Br. Med. J., 1998, 316, 1328.
19. Janssen J.A., Lamberts S.W. Circulating: IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin. Endocrinol., 2002, 52, 1.
20. Johansson J.O., Fowelin J., Landin K. i wsp.: Growth hormone-deficient adults are insulin resistant. Metab. Clin. Exp., 1995, 44, 1126.
21. Kajdaniuk D., Marek B., Ṡwiȩtochowska E. i wsp.: Insulinopodobny czynnik wzrostowy-I aspekty patofizjologiczne i kliniczne. Polski Merkuriusz Lekarski, 1999, 41, 205.
22. Kinalska I., Kowalska I.: Kliniczne i metaboliczne efekty działania GH-IGF-1 u dorosłych: wpływ na gospodarkȩ wȩglowodanowa̧, lipidowa̧, białkowa̧ i układ krzȩpniȩcia. Endokrynol. Pol., 1999, 40, supl. 2, 71.
23. Korolkiewicz R.P., Tashima K., Fujita A. i wsp.: Exogenous insulin-like growth factor (IGF)-I improves the impaired healing of gastric mucosal lesions in diabetic rats. Pharmacol. Res., 2000, 41, 221.
24. Krasowski J.: Zaburzenia wydzielania hormonu wzrostu w cukrzycy typu 1. Diabetol. Pol., 1998, 5, 62.
25. Krassowski J., Jeske W., Zgliczynski S.: Increased 24-hour growth hormone secretion in type 1 diabetes mellitus. Endokrynol. Pol., 1994, 45, 173.
26. Lu M., Adamis A.P.: Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol. Clin. North. Am., 2002, 15, 69.
27. Malamitsi-Puchner A., Sarandakou A., Tziotis J. i wsp.: Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus. Pediatr. Res., 1998, 44, 873.
28. Malecaze F., Clamens S., Simorre-Pinatel V. i wsp.: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol., 1994, 112, 1476.
29. Matthew M., Syces R.B.: Regulatory actions of insulin-like growth factor - binding proteins. TEM, 1998, 9, 176.
30. McLaren M., Elhadd T.A., Greene S.A. i wsp.: Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin. Appl. Thromb. Hemost., 1999, 5, 21.
31. Mooler N., Orskov H.: Growth hormone, IGF-1 and diabetic angiopathy revisited. Clin. Endocrinol., 2000, 52, 11.
32. Niedźwiecka A.: Insulinopodobny czynnik wzrostowy 1 (somato-medyna C) i jego białka wia̧ża̧ce 1 i 3 u dzieci, ze szczególnym uwzglȩdnieniem cukrzycy. Endokrynologia, Diabetologia i Choroby Przemiany Materii Wieku Rozwojowego, 2000, 11, 51.
33. Noma H., Funatsu H., Yamashita H. i wsp.: Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch. Ophthalmol., 2002, 120, 1075.
34. Ogata N., Nishikawa M., Nishimura T. i wsp.: Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am. J. Ophthalmol., 2002, 134, 348.
35. Romer T.E.: Rola hormonów w procesie wzrastania. Klin. Pediatr., 1997, 5, 190.
36. Rosmussen Lautier C., Hansen L. i wsp.: Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. J. Clin. Endocrinol. Metab., 2000, 85, 1606.
37. Santilli F., Spagnoli A., Mohn A. i wsp.: Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J. Clin. Endocrinol. Metab., 2001, 8, 3871.
38. Sen A., Buyukgebiz A.: Albumin excretion rate, serum insulin-like growth factor-1 and glomerular filtra diabetes mellitus at puberty. J. Pediatr. Endocrinol. Metab., 1997, 10, 209.
39. Shinada M., Akdaniz A., Panagiotopoulos S. i wsp.: Proteolysis of insulin-like factor-binding protein-3 is increased in urine from patients with diabetic nephropathy. J. Clin. Endocrinol. Matab., 2000, 85, 1163.
40. Simo R., Lecube A., Segura R.M. i wsp.: Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am. J. Ophthalmol., 2002, 134, 376.
41. Sone H., Kawakami Y., Segawa T. i wsp.: Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy. Life Sci., 1999, 65, 2573.
42. Spagnoli A., Chiarelli F., Vorwerk P. i wsp.: Evaluation of the components of insulin-like growth factor (IGF) - IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18 kD N-terminal fragment. Clin. Endocrinol., 1999, 51, 587.
43. Vuorela P., Andersson D.S., Carpen O. i wsp.: Unbound vascular endothelial growth factor and its receptors in breast, human milk, and newborn intestine. Am. J. Clin. Nutr., 2000, 72, 1196.
44. Wollman H.A., Ranke M.B.: Metabolic effects of growth hormone in children. Metabolism, 1995, 44, supl. 4, 97.
45. Zachary T.: Diabetic nephropathy. 36th Annual meeting of the Europen Association for the Study of Diabetes, September 17, 2000.
46. Zanchi A., Moczulski D.K., Hanna L.S. i wsp.: Risk of advanced diabetic naphropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int., 2000, 57, 405.